ATE534400T1 - Pharmakologische vitreolyse unter verwendung eines verkürzten plasmins - Google Patents

Pharmakologische vitreolyse unter verwendung eines verkürzten plasmins

Info

Publication number
ATE534400T1
ATE534400T1 AT03812818T AT03812818T ATE534400T1 AT E534400 T1 ATE534400 T1 AT E534400T1 AT 03812818 T AT03812818 T AT 03812818T AT 03812818 T AT03812818 T AT 03812818T AT E534400 T1 ATE534400 T1 AT E534400T1
Authority
AT
Austria
Prior art keywords
eye
reduce
vitreous
plasmin
disorder
Prior art date
Application number
AT03812818T
Other languages
English (en)
Inventor
Steve Pakola
Smet Marc De
Original Assignee
Thrombogenics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9949140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE534400(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thrombogenics Nv filed Critical Thrombogenics Nv
Application granted granted Critical
Publication of ATE534400T1 publication Critical patent/ATE534400T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02005—Chondroitin AC lyase (4.2.2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
    • C12Y402/02019—Chondroitin B lyase (4.2.2.19)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Insulating Materials (AREA)
AT03812818T 2002-12-06 2003-12-05 Pharmakologische vitreolyse unter verwendung eines verkürzten plasmins ATE534400T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228409.9A GB0228409D0 (en) 2002-12-06 2002-12-06 Pharmacological vitreolysis
PCT/US2003/038714 WO2004052228A2 (en) 2002-12-06 2003-12-05 Pharmacological vitreolysis

Publications (1)

Publication Number Publication Date
ATE534400T1 true ATE534400T1 (de) 2011-12-15

Family

ID=9949140

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03812818T ATE534400T1 (de) 2002-12-06 2003-12-05 Pharmakologische vitreolyse unter verwendung eines verkürzten plasmins

Country Status (24)

Country Link
US (11) US7547435B2 (de)
EP (3) EP2327416B1 (de)
JP (4) JP5426063B2 (de)
CN (1) CN100577202C (de)
AT (1) ATE534400T1 (de)
AU (1) AU2003300821C1 (de)
BE (1) BE2013C055I2 (de)
BR (2) BR0317033A (de)
CA (1) CA2508606C (de)
CY (2) CY1112561T1 (de)
DK (1) DK1581254T3 (de)
ES (2) ES2377965T3 (de)
FR (1) FR13C0052I2 (de)
GB (1) GB0228409D0 (de)
HU (1) HUS1300040I1 (de)
IL (3) IL169008A (de)
LU (1) LU92273I2 (de)
MX (1) MXPA05006038A (de)
NO (4) NO333837B1 (de)
NZ (1) NZ541075A (de)
PT (2) PT1581254E (de)
SI (1) SI1581254T1 (de)
WO (1) WO2004052228A2 (de)
ZA (1) ZA200505193B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7152975B2 (en) * 2000-11-10 2006-12-26 Cooper Vision, Inc. Junctionless ophthalmic lenses and methods for making same
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN102660564B (zh) 2004-04-22 2013-05-08 泰勒克里斯生物治疗学公司 重组修饰的纤溶酶
JP4796787B2 (ja) 2005-04-28 2011-10-19 富士フイルム株式会社 ラビリンチュラ類への遺伝子導入法
US20060257391A1 (en) * 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
WO2007005856A1 (en) * 2005-06-30 2007-01-11 Ista Pharmaceuticals, Inc. Use of hyaluronidase in combination with plasmin for the induction of posterior vitreous detachment
WO2007047874A2 (en) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
US20070134231A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes and compositions thereof
US20070134230A1 (en) * 2005-12-13 2007-06-14 Jani Dharmendra M Method for prolonging activity of autodegradable enzymes
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
AU2007247426B2 (en) * 2006-05-04 2012-03-08 Fondation Ophthalmologique Adolf De Rothschild Combination comprising a VEGF inhibitor and a serine protease for treating neovascular diseases
ES2534040T3 (es) * 2007-11-29 2015-04-16 Grifols Therapeutics Inc. Plasmina modificada de forma recombinante
WO2009093970A1 (en) * 2008-01-22 2009-07-30 Omnio Healer Ab Method of improving wound healing
CA2719981A1 (en) * 2008-03-31 2009-10-08 Scarcell Therapeutics Method for the cosmetic treatment of skin ageing
CN102057044B (zh) * 2008-06-04 2013-05-01 泰勒克里斯生物治疗学公司 用于制备纤溶酶的组合物，方法以及试剂盒
JP5789521B2 (ja) 2009-03-03 2015-10-07 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン
US8858924B2 (en) * 2009-03-26 2014-10-14 Warsaw Orthopedic, Inc. Compositions and methods for treatment of hemorrhage
CN102482338B (zh) 2009-07-10 2016-09-28 斯路姆基因公司 纤溶酶原和纤溶酶的变体
EP2480249B1 (de) 2009-08-28 2015-01-28 ThromboGenics N.V. Plasmin zur Behandlung von Filtrationsfehlern nach Trabeculektomie
US20110135626A1 (en) * 2009-12-08 2011-06-09 Alcon Research, Ltd. Localized Chemical Lysis of Ocular Tissue
RU2435553C1 (ru) * 2010-03-10 2011-12-10 Арсений Александрович Кожухов Способ лечения центральных субретинальных кровоизлияний
RU2604807C2 (ru) 2011-01-05 2016-12-10 ТромбоДженикс НВ Варианты плазминогена и плазмина
US20120329873A1 (en) * 2011-06-17 2012-12-27 Li yong-xin D-serine for the treatment of visual system disorders
AU2012296884B2 (en) 2011-08-12 2015-02-05 Thrombogenics N.V. Plasminogen and plasmin variants
RU2484795C2 (ru) * 2011-08-18 2013-06-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ индукции задней отслойки стекловидного тела с помощью миниплазмина
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
CN103205410B (zh) * 2012-01-13 2018-03-06 蔺莹莹 重组微纤维蛋白溶酶及其制备方法和应用
EP2841454A1 (de) 2012-04-24 2015-03-04 ThromboGenics N.V. Anti-pdgf-c-antikörper
JP6483083B2 (ja) * 2013-03-14 2019-03-13 ウェイン ステイト ユニバーシティー 治療用化合物の眼への送達を増強する方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016054079A1 (en) 2014-09-29 2016-04-07 Zyomed Corp. Systems and methods for blood glucose and other analyte detection and measurement using collision computing
FR3034992A1 (fr) 2015-04-15 2016-10-21 Arcadophta Milieu plasmatique ex vivo autologue riche en plasmine et procede d'obtention
DK3395353T5 (da) 2015-12-18 2024-09-30 Talengen Int Ltd Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade
CA3008691A1 (en) 2015-12-18 2017-06-22 Talengen International Limited Method for preventing or treating diabetic retinopathy
JP6682008B2 (ja) * 2015-12-18 2020-04-15 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病性腎症を予防及び治療するための方法
SG11201805420SA (en) 2015-12-30 2018-07-30 Kodiak Sciences Inc Antibodies and conjugates thereof
RU2619991C1 (ru) * 2016-02-18 2017-05-22 Павел Владимирович Лыскин Способ лечения витреомакулярного тракционного синдрома
EP3426685A1 (de) 2016-03-10 2019-01-16 Oxurion NV Hintere okularfibrosehemmung durch antagonisierung des plazentalen wachstumsfaktors
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
JP7554557B2 (ja) 2016-12-15 2024-09-20 タレンゲン インターナショナル リミテッド インスリン受容体基質－２の発現を促進する方法
AU2018242882B2 (en) 2017-03-28 2021-08-12 Morinaga Milk Industry Co., Ltd. Novel Bifidobacterium genus bacterium
RU2674926C1 (ru) * 2018-02-01 2018-12-13 Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ "МНТК "Микрохирургия глаза" им. акад. С.Н. Способ оценки эффективности витреолизиса помутнений стекловидного тела
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN110361242B (zh) * 2019-08-14 2022-01-18 武汉赛维尔生物科技有限公司 一种用于眼球组织的固定液以及眼球组织制片的预处理方法
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
CN116716251A (zh) * 2023-06-20 2023-09-08 中国医学科学院北京协和医院 一种玻璃体样本的单细胞处理方法及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658972A (en) * 1900-04-09 1900-10-02 Interchangeable Brake Beam Company Brake-beam.
US2624691A (en) 1946-04-22 1953-01-06 Parke Davis & Co Fibrinolysin derived from blood and methods of obtaining the same
DK98833C (da) 1961-04-25 1964-05-25 Novo Terapeutisk Labor As Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger.
US3234106A (en) 1962-12-03 1966-02-08 Cutter Lab Soluble, purified profibrinolysin and fibrinolysin and method of producing same
US3950513A (en) 1965-12-03 1976-04-13 Novo Terapeutisk Laboratorium A/S Process of stabilizing therapeutically useful plasmin solutions
IT1194135B (it) 1981-01-05 1988-09-14 Novo Industri As Composizioni di plasmina stabilizzata e metodo per la loro preparazione
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US4774087A (en) 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US5288485A (en) 1989-08-31 1994-02-22 Kao Corporation Vasodilating agent
ZA912770B (en) 1990-04-16 1992-01-29 Bethesda Eye Inst Enzymatic disinsertion of vitreous body
US5288489A (en) 1991-08-28 1994-02-22 Orion Therapeutic Systems, Inc. Fibrinolysis and fibrinogenolysis treatment
WO1994001128A1 (en) 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
US5304118A (en) * 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
US6610292B2 (en) 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US5866120A (en) 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US5973779A (en) 1996-03-29 1999-10-26 Ansari; Rafat R. Fiber-optic imaging probe
US6207066B1 (en) 1996-07-23 2001-03-27 Nuvue Technologies, L.L.C. Method for purification of a blood component
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5722428A (en) 1996-10-29 1998-03-03 Washington University Method for producing a posterior vitreous detachment
US6596725B2 (en) 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
KR100566451B1 (ko) 1997-05-22 2006-03-31 이스타 파마슈티칼스, 인크. 안질환 치료에서 초자체액의 액화를 위한 안과용 제제의 제조에 있어서의 히알루로니다제의 용도
CN1322126C (zh) 1998-02-04 2007-06-20 思罗姆-X股份有限公司 免疫原性降低和/或清除率降低的葡激酶衍生物的鉴定、生产和应用
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6462071B1 (en) 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US20040081643A1 (en) 1999-03-09 2004-04-29 Peyman Gholam A. Process for inhibiting vascular proliferation in the eye
US6733750B1 (en) 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US6585972B2 (en) 1999-03-09 2003-07-01 Gholam A. Peyman Process for crosslinking of collagen in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
EP1229116A4 (de) 1999-11-10 2003-01-22 Ct For Advanced Science & Tech Verfahren zur herstellung einer zellfraktion, welche hemangioblasten beinhaltet
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
EP1297016B1 (de) * 2000-05-12 2006-03-22 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
US7445775B2 (en) 2000-12-21 2008-11-04 Thromb-X Nv Yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
US20020139378A1 (en) * 2001-03-28 2002-10-03 Trese Michael T. Method for creating a separation of posterior cortical vitreous from the retina of the eye
FI20011132A0 (fi) 2001-05-30 2001-05-30 Innovationsagentur Markkeri hematopoieettisten kantasolujen tunnistamiseen
US7776026B2 (en) 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
US20040235115A1 (en) * 2002-11-18 2004-11-25 Reed Guy L. Compositions and methods for treating thrombotic disorders
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US20070212358A1 (en) * 2006-03-10 2007-09-13 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment

Also Published As

Publication number Publication date
US20130195887A1 (en) 2013-08-01
SI1581254T1 (sl) 2012-05-31
US7914783B2 (en) 2011-03-29
IL213838A0 (en) 2011-07-31
JP5996026B2 (ja) 2016-09-21
JP2006518708A (ja) 2006-08-17
CY1112561T1 (el) 2015-11-04
US8383105B2 (en) 2013-02-26
EP2327416B1 (de) 2019-05-01
BE2013C055I2 (de) 2023-03-07
EP2327415B1 (de) 2017-10-18
LU92273I9 (de) 2019-01-15
NZ541075A (en) 2008-02-29
US7547435B2 (en) 2009-06-16
FR13C0052I2 (fr) 2014-11-21
US20130202613A1 (en) 2013-08-08
IL202851A0 (en) 2011-07-31
US20130302304A1 (en) 2013-11-14
US7803368B2 (en) 2010-09-28
US20090081187A1 (en) 2009-03-26
US8747842B2 (en) 2014-06-10
ZA200505193B (en) 2007-08-29
US20150064161A1 (en) 2015-03-05
LU92273I2 (fr) 2013-10-29
NO2013016I1 (no) 2013-11-19
CA2508606A1 (en) 2004-06-24
US8460655B2 (en) 2013-06-11
EP1581254A4 (de) 2007-03-28
BRPI0310144A8 (pt) 2018-04-24
IL202851A (en) 2015-04-30
NO20121170A1 (no) 2012-10-12
AU2003300821A1 (en) 2004-06-30
EP2327416A1 (de) 2011-06-01
EP1581254A2 (de) 2005-10-05
US20090074739A1 (en) 2009-03-19
AU2003300821C1 (en) 2012-03-22
US9770494B2 (en) 2017-09-26
CA2508606C (en) 2015-07-28
CY2013033I1 (el) 2015-11-04
CN1738641A (zh) 2006-02-22
DK1581254T3 (da) 2012-02-27
GB0228409D0 (en) 2003-01-08
HK1082419A1 (en) 2006-06-09
HUS1300040I1 (hu) 2013-08-15
CN100577202C (zh) 2010-01-06
NO20052988L (no) 2005-09-05
JP5426063B2 (ja) 2014-02-26
JP2010222369A (ja) 2010-10-07
JP2015131842A (ja) 2015-07-23
WO2004052228A3 (en) 2004-10-07
ES2377965T3 (es) 2012-04-03
JP5451533B2 (ja) 2014-03-26
ES2731625T3 (es) 2019-11-18
US20050118158A1 (en) 2005-06-02
IL169008A (en) 2011-08-31
WO2004052228A2 (en) 2004-06-24
US7867489B2 (en) 2011-01-11
MXPA05006038A (es) 2006-03-08
US20110300123A1 (en) 2011-12-08
JP2013241448A (ja) 2013-12-05
JP5739487B2 (ja) 2015-06-24
EP1581254B1 (de) 2011-11-23
BR0317033A (pt) 2005-10-25
US8834869B2 (en) 2014-09-16
PT2327416T (pt) 2019-07-04
NO343759B1 (no) 2019-06-03
US20110171190A1 (en) 2011-07-14
NO20052988D0 (no) 2005-06-17
CY2013033I2 (el) 2015-11-04
PT1581254E (pt) 2012-02-06
FR13C0052I1 (de) 2013-04-10
US20080050356A1 (en) 2008-02-28
NO2013016I2 (no) 2017-06-28
US9186394B2 (en) 2015-11-17
NO333837B1 (no) 2013-09-30
EP2327415A1 (de) 2011-06-01
US20080095753A1 (en) 2008-04-24
NO20121169A1 (no) 2012-10-12
AU2003300821B2 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
ATE534400T1 (de) Pharmakologische vitreolyse unter verwendung eines verkürzten plasmins
ATE429914T1 (de) Verwendung von makroliden zur wiederherstellung der kornealempfindungen
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
DE60138137D1 (de) Verfahren und zusammensetzungen zur behandlung von okularer neovaskularisierung und nervenverletzungen
Nakano et al. Intraoperative microkeratome complications in 47,094 laser in situ keratomileusis surgeries
CR8453A (es) Metodo para el tratamiento de trastornos oftalmicos
AR036199A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
ATE535257T1 (de) Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin
DK1263363T3 (da) Farvet viskoelastisk sammensætning
Maguen et al. Extracellular matrix and matrix metalloproteinase changes in human corneas after complicated laser-assisted in situ keratomileusis (LASIK)
Miao et al. Diffusion of macromolecules through sclera
AR031288A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
ATE550015T1 (de) Verfahren und zusammensetzung zur behandlung von rhinitis
MX2007010295A (es) Composiciones oftalmologicas novedosas y metodo para su uso.
ATE253905T1 (de) Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina
Yoon et al. Recurrent herpes simplex keratitis after verteporfin photodynamic therapy for corneal neovascularization
Velez et al. Retinal pigment epithelium and Müller progenitor cell interaction increase Müller progenitor cell expression of PDGFRα and ability to induce proliferative vitreoretinopathy in a rabbit model
ATE293969T1 (de) Verwendung von hydroxyeicosatetraensäure für intraokuläre chirurgie
PL430675A1 (pl) Bromokryptyna do zastosowania w leczeniu chorób oczu związanych z podwyższonym poziomem śródbłonkowego czynnika wzrostu naczyń (VEGF) oraz kompozycja farmaceutyczna zawierająca bromokryptynę
AR058617A1 (es) Metodo para el tratamiento de formas primarias y secundarias de glaucoma
UA86346C2 (ru) Способ лечения открытоугольной глаукомы